Viridian Therapeutics Inc (NAS:VRDN)
$ 12.34 0.74 (6.38%) Market Cap: 787.57 Mil Enterprise Value: 347.92 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 46/100

Q3 2022 Viridian Therapeutics Inc Earnings Call Transcript

Nov 14, 2022 / 01:00PM GMT
Release Date Price: $20.32 (-0.93%)
Operator

Greetings, and welcome to Viridian Therapeutics Third Quarter 2022 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, John Jordan, Vice President of Investor Relations. Please go ahead.

John A. Jordan
Viridian Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, Brock. Good morning, everyone, and welcome to the Viridian conference call to discuss the positive clinical data reported earlier today for VRDN-001 in patients with thyroid eye disease. Before we begin, I'd like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ.

Please note that these forward-looking statements reflect our opinions only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot